Cytokinetics, Amgen increase scope of heart failure deal

Amgen and Cytokinetics agreed to expand an existing licensing deal centered on the experimental heart failure drug omecamtiv mecarbil and related compounds to include the Japanese market. The expanded deal entitles Cytokinetics to $25 million in upfront payment and as much as $50 million in milestone fees plus sales royalties.

View Full Article in:

Los Angeles Business Journal (free registration) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC